

AbbVie Pipeline Update

January 2025



abbvie

AbbVie R&D Pipeline

Phase 1

- CUG-252* (IL-2 Mutein) SLE
- ABBV-8736 (TREM1) IBD
- Livmoniplimab (GARP+TGFβ1) Solid Tumors
- Temab-A (ABBV-400) (c-Met ADC) NSCLC
- ABBV-706 (SEZ6 ADC) SCLC
- ABBV-CLS-579* (PTPN2) Solid Tumors
- ABBV-CLS-484* (PTPN2) Solid Tumors
- ABBV-514 (CCR8) Solid Tumors
- ABBV-303 (c-Met TRINKET) Solid Tumors
- ABBV-969 (PSMA/STEAP1 ADC) mCRPC
- IMGN-151 (FRα ADC) Ovarian Cancer
- IMGN-151 (FRα ADC) Endometrial Cancer
- UB-VV111* (CD19) Heme Tumors
- Etentamig (ABBV-383) (CD3-BCMA) R/R MM Combinations
- Etentamig (ABBV-383) (CD3-BCMA) AL Amyloidosis
- ABBV-319 (CD19/Steroid ADC) Heme Tumors
- ABBV-525 (MALT1) Heme Tumors
- ABBV-453 (BCL-2) R/R MM t(11;14)/BCL2 High
- ABBV-453 (BCL-2) R/R CLL
- Epkinly* (CD3-CD20) R/R CLL and Richter's Syndrome
- ABBV-101 (BTK Degrader) R/R NHL
- ABBV-CLS-7262* (eIF2B) VWM Disease
- ABBV-CLS-7262* (eIF2B) MDD
- ABBV-1088 (PINK1) Parkinson's Disease
- ABBV-1758 (3pE-Aβ) Alzheimer's Disease
- Emraclidine (M4 PAM) AD Psychosis
- ABBV-1354 (KOR Antagonist) Depression
- ABBV-141 (LPAR1) SSc & IPF
- ABBV-142 (LPAR1) SSc & IPF
- ABBV-722 (LPAR1) SSc & IPF

Phase 2

- Lutikizumab (IL-1α/1β) UC
- Lutikizumab (IL-1α/1β) Atopic Dermatitis
- Lutikizumab (IL-1α/1β) + Skyrizi* (IL-23) CD
- ABBV-382 (α4β7) + Skyrizi* (IL-23) CD
- OpSCF* (Stem Cell Factor mAb) AD
- ABBV-113 (NLRX1) UC
- Epkinly* (CD3-CD20) B-Cell NHL
- Temab-A (ABBV-400) (c-Met ADC) 1L GEA
- Livmoniplimab (GARP+TGFβ1) 1L HCC
- Livmoniplimab (GARP+TGFβ1) 2L HCC
- Livmoniplimab (GARP+TGFβ1) 1L NSCLC
- Livmoniplimab (GARP+TGFβ1) 2L+ mUC
- TTX-030* (CD39) Pancreatic Cancer
- Budigalimab (PD-1) Solid Tumors
- Elahere (FRα ADC) PSOC (420)
- Pivekimab Sunirine (CD123 ADC) AML
- Emraclidine (M4 PAM) Schizophrenia
- ABBV-932* (D2/D3 Agonist) Bipolar Disorder
- Botox Essential Tremor
- Elezanumab (RGMa) Spinal Cord Injury
- Darigabat (GABA_A PAM) Panic Disorder
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucoma
- ABBV-1882 (anti-PD1/anti-a4b7) HIV

Registrational / Phase 3

- Rinvoq (JAK 1) Alopecia Areata
- Rinvoq (JAK 1) HS
- Rinvoq (JAK 1) SLE
- Rinvoq (JAK 1) Vitiligo
- Lutikizumab (IL-1α/1β) HS
- Venclexta* (BCL-2) AML Post-Transplant
- Venclexta* (BCL-2) Higher Risk MDS
- Epkinly* (CD3-CD20) 1L DLBCL
- Epkinly* (CD3-CD20) R/R DLBCL
- Epkinly* (CD3-CD20) 1L FL
- Epkinly* (CD3-CD20) R/R FL
- Etentamig (ABBV-383) (CD3-BCMA) 3L+ MM
- Teliso-V (c-Met ADC) 2L+ NSCLC
- Temab-A (ABBV-400) (c-Met ADC) 3L+ CRC
- Elahere (FRα ADC) PSOC (GLORIOSA)
- Pivekimab Sunirine (CD123 ADC) BPDCN
- Tavapadon (D1/D5 Partial Agonist) Parkinson's Disease
- BoNT/E Glabellar Lines
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery
- Armour Thyroid (T3T4) Hypothyroidism

Submitted

- Rinvoq (JAK 1) GCA
- Teliso-V (c-Met ADC) 2L+ NSCLC
- Reproxalap (RASP)* Dry Eye Disease
- Aztreonam/Avibactam* (PBP3) Infection

- Immunology
- Oncology
- Neuroscience
- Aesthetics
- Eye Care
- Targeted Investment

As of January 31, 2025

Excludes devices in development; *AbbVie Partnered assets

AbbVie - Anticipated Key Pipeline Events

	2025	2026
Regulatory Approvals	Rinvoq GCA Teliso-V 2L+ NSCLC (AA)	Rinvoq Vitiligo Venclexta Higher Risk MDS Pivekimab Sunirine BPDCN Tavapadon Parkinson's Disease BoNT/E Glabellar Lines
Regulatory Submissions	Venclexta Higher Risk MDS Pivekimab Sunirine BPDCN Tavapadon Parkinson's Disease BoNT/E Glabellar Lines	Rinvoq Vitiligo Rinvoq Alopecia Areata Rinvoq Hidradenitis Suppurativa Epkinly 2L DLBCL Transplant Ineligible
Ph3/Registrational Data Readouts	Rinvoq Ph3 Alopecia Areata Rinvoq Ph3 Vitiligo Skyrizi Ph3 Psoriasis H2H versus Deucravacitinib Venclexta Ph3 Higher Risk MDS	Rinvoq Ph3 Hidradenitis Suppurativa Rinvoq Ph3 Systemic Lupus Erythematosus Epkinly Ph3 2L DLBCL Transplant Ineligible Epkinly Ph3 1L DLBCL ABBV-RGX-314 Ph3 wAMD Subretinal Delivery
Early-Stage Data Readouts	ABBV-113 Ph2 UC Temab-A Ph1 NSCLC EGFR Mutant ABBV-706 Ph1 SCLC Livmoniplimab Ph2 1L & 2L HCC Botox Therapeutic Ph2 Essential Tremor	Lutikizumab Ph2 UC ABBV-969 Ph1 mCRPC ABBV-101 Ph1 R/R NHL Etentamig Ph1 1L & 2L MM combinations Livmoniplimab Ph2 1L NSCLC ABBV-932 Ph2 Bipolar Disorder ABBV-932 Ph2 Generalized Anxiety Disorder ABBV-1354 Ph2 Bipolar Depression ABBV-RGX-314 Ph2 wAMD Suprachoroidal Delivery
Select Study Starts	Skyrizi Ph3 UC H2H versus Vedolizumab Skyrizi + Lutikizumab Ph2 PsA ABBV-8736 Ph2 CD ABBV-932 Ph2 Generalized Anxiety Disorder ABBV-1354 Ph2 Bipolar Depression	Lutikizumab Ph3 UC ABBV-701 + Skyrizi Ph2 IBD Etentamig Ph3 2L+ MM Combination Therapy Emraclidine Ph2 Adjunctive Schizophrenia Emraclidine Ph2 AD/PD/DLB Psychosis ABBV-932 Ph3 Bipolar Disorder

As of January 31, 2025
AA = Accelerated Approval

AbbVie's Partnered Assets

- ABBV-932 developed in partnership with Gedeon Richter
- ABBV-CLS-579/484/7262 co-developed by Calico and AbbVie
- ABBV-RGX-314 co-developed by REGENXBIO and AbbVie
- Aztreonam/Avibactam co-developed by Pfizer and AbbVie
- CUG-252 developed by Cugene through Phase 1b and AbbVie holds option for additional development
- Epkinly developed in partnership with Genmab
- OpSCF co-developed by Opsidio and AbbVie
- Reproxalap currently developed by Aldeyra. AbbVie holds an exclusive option to license, co-develop, and co-commercialize reproxalap.
- Skyrizi developed in cooperation with Boehringer Ingelheim
- TTX-030 developed by Trishula Therapeutics through Phase 2 and AbbVie has option to lead global development
- UB-VV111 developed by Umoja Biopharma. AbbVie holds an exclusive option to develop and commercialize UB-VV111.
- Venclexta jointly developed with Roche